Durin Hires Former GE HealthCare Exec Dr. Mert Sahin as CEO

Durin Technologies, a company specializing in neurodegenerative disease diagnostic testing, has appointed Dr. Mert Sahin as its new CEO.
 
Dr. Sahin has over 20 years of experience in life sciences, pharmaceuticals, and medical devices. His previous roles include executive positions at GE HealthCare, where he led marketing for its molecular imaging business in the U.S. and Canada.
 
He also held various commercial positions at Roche Diagnostics, Eurofins Genomics, Thermo Fisher Scientific, and Dalan Animal Health. Dr. Shain co-founded BioProcess, a company that helps alternative protein ingredient companies transition from the lab to commercial scale.
 
He will lead Durin as it commercializes its novel diagnostic tests for Alzheimer’s and Parkinson’s diseases, and develops its next generation of diagnostic tests for other diseases and disorders at their earliest stages.
 
Dr. Robert Nagele, Durin’s founder and chief scientific officer, told the press, “Dr. Sahin’s team-centric, lead-by-example leadership style and innovative approach to fostering growth make him an excellent fit for Durin’s aggressive growth plans. We’re confident that his strategic vision, expertise, and determination will propel the company forward and allow Durin to seize the significant market opportunities available.”
 
Durin’s rapid-result, high-accuracy Duritect diagnostic tests make early detection and monitoring of disease progression possible—in a decade or more prior to symptoms in some cases, the company said. Its first two tests for Alzheimer’s and Parkinson’s are expected to hit the market in 2024, followed by tests for some other diseases.
 
“I am excited to join Durin, which will quickly become the innovation leader in neurodegenerative disease diagnostics,” said Dr. Sahin. “I look forward to working closely with the team to advance Durin to the next stage of its commercial success.”